ERBB2 K753E

CI-VAR-00002176Explore in graph →NP_001276866.1:p.Lys753GluNM_001289937.1:c.2257A>GCIViC 1312

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
ERBB2 K753E	Lapatinib	Predictive	D	Supports Resistance	3	submitted	EID3024 K753E was identified in 6/338 HER2-positive tumors (2/1248 total tumors). In vitro studies showed that MCF10A cells with HER2 K753E were more resistant to lapatinib treatment in comparison to HER2 WT … (full text at CIViC) PMID 27697991 · Zuo et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.